Literature DB >> 24706279

Mouse model of experimental dermal fibrosis: the bleomycin-induced dermal fibrosis.

Jérôme Avouac1.   

Abstract

Relevant animal models are essential tools to investigate in depth the pathogenesis of autoimmune disease. Systemic sclerosis (SSc) is an autoimmune connective tissue disorder that affects particularly the skin. SSc is characterized by vasculopathy, immune disturbances, and fibrosis. Expression of each of the three pathologic features varies among SSc patients leading to disease heterogeneity and variable organ manifestations. Several animal models of SSc are available; however, some models display inflammation followed by fibrosis, whether some others primarily mimic autonomous fibroblast activation. Here, we describe the mouse model of bleomycin-induced dermal fibrosis, which mimics early and inflammatory stages of SSc, and is widely used in SSc research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706279     DOI: 10.1007/978-1-4939-0404-4_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Authors:  Dylan J Kahl; Kim M Hutchings; Erika Mathes Lisabeth; Andrew J Haak; Jeffrey R Leipprandt; Thomas Dexheimer; Dinesh Khanna; Pei-Suen Tsou; Phillip L Campbell; David A Fox; Bo Wen; Duxin Sun; Marc Bailie; Richard R Neubig; Scott D Larsen
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

2.  Liver damage in bleomycin-induced pulmonary fibrosis in mice.

Authors:  V R Vásquez-Garzón; A Ramírez-Cosmes; E Reyes-Jiménez; G Carrasco-Torres; S Hernández-García; S R Aguilar-Ruiz; H Torres-Aguilar; J Alpuche; L Pérez-Campos Mayoral; S Pina-Canseco; J Arellanes-Robledo; S Villa-Treviño; R Baltiérrez-Hoyos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-16       Impact factor: 3.000

3.  VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.

Authors:  Carmen Del Rio; Irene Cantarero; Belén Palomares; María Gómez-Cañas; Javier Fernández-Ruiz; Carolina Pavicic; Adela García-Martín; Maria Luz Bellido; Rafaela Ortega-Castro; Carlos Pérez-Sánchez; Chary López-Pedrera; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2018-08-23       Impact factor: 8.739

4.  Role of STAT3 in skin fibrosis and transforming growth factor beta signalling.

Authors:  Mesias Pedroza; Sarah To; Shervin Assassi; Minghua Wu; David Tweardy; Sandeep K Agarwal
Journal:  Rheumatology (Oxford)       Date:  2018-10-01       Impact factor: 7.580

5.  Scleroderma-like Impairment in the Network of Telocytes/CD34+ Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis.

Authors:  Irene Rosa; Eloisa Romano; Bianca Saveria Fioretto; Daniele Guasti; Lidia Ibba-Manneschi; Marco Matucci-Cerinic; Mirko Manetti
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

6.  Gut Microbiota Aberration in Patients of Systemic Sclerosis and Bleomycin-Induced Mice Model.

Authors:  Jungen Tang; Xin Zhou; Xuefen Wu; Shengyan Lin; Bingxia Ming; Jixin Zhong; Baoju Wang; Lingli Dong
Journal:  Front Cell Infect Microbiol       Date:  2021-05-28       Impact factor: 5.293

7.  Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

Review 8.  Regulation of CAR and PXR Expression in Health and Disease.

Authors:  Martine Daujat-Chavanieu; Sabine Gerbal-Chaloin
Journal:  Cells       Date:  2020-10-31       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.